Opdivo for Metastatic Renal Cell Carcinoma – Details


( Last Updated : September 19, 2016)
Generic Name:
Nivolumab
Project Status:
Complete
Therapeutic Area:
Metastatic Renal Cell Carcinoma
Manufacturer:
Bristol Myers-Squibb Canada
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0074-000
NOC Status at Filing:
Pre NOC
NOC Date:

Details


Strength:
40mg and 100mg vials
Tumour Type:
Genitourinary
Indications:
Metastatic Renal Cell Carcinoma
Funding Request:
For advanced or metastatic renal cell carcinoma in patients who have received prior systemic therapy
Pre Noc Submission:
Yes
Sponsor:
Bristol Myers-Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
Please note that the August pERC meeting was conducted over two days. The original target date for the posting of pERC Final Recommendation remains as September 1, 2016.
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.